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of hydrocortisone. Transfection efficiency was reduced by 
the presence of methotrexate and not significantly affected 
by infliximab.  Conclusion: Gene therapy is a potential future 
strategy for the management of PG; this study is a step to-
wards the development of a topical gene-based agent. 
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 Introduction 
 Pyoderma gangrenosum (PG) is a rare neutrophilic 
dermatosis, characterised by painful cutaneous ulcers  [1] , 
with an annual incidence of 3–10 per million  [1] . Al-
though relatively uncommon, the ulcers of PG are exqui-
sitely painful, and, like many skin disorders, the disease 
has a significant negative impact on quality of life. Pa-
tients with PG are often systemically unwell, and extracu-
taneous manifestations have been described  [1] . Around 
50% of cases are associated with a systemic disease, most 
commonly inflammatory bowel disease, rheumatoid ar-
thritis, and haematological malignancy  [2] . The patho-
genesis is not known, but inflammatory and immuno-
logical processes are thought to be the underlying mecha-
nisms  [3] . Current treatment is mostly empirical, with 
corticosteroids and other immunosuppressants as first 
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 Abstract 
 Background/Aims: Pyoderma gangrenosum (PG) is a rare 
ulcerative skin disease, currently treated empirically with 
immunosuppression. PG is a good target for gene therapy 
since the skin is easily accessible. This study used the FDA-
approved vector Lipofectamine ® 2000 to investigate in vi-
tro  transfection of skin keratinocytes. The aim was to deter-
mine an optimum transfection protocol, including the ef-
fect of drugs currently used to treat PG on the efficiency of 
gene transfer, since gene therapy is unlikely to be used as 
monotherapy.  Methods: Cells of the HaCaT line were trans-
fected with the lacZ reporter gene, and transgene expres-
sion was measured after a given time period. Conditions 
tested were: relative concentrations of DNA and Lipofec-
tamine ® , time from transfection to measurement of expres-
sion, pH, and exposure to clinically relevant drugs (hydro-
cortisone, methotrexate, infliximab).  Results: The greatest 
levels of β-galactosidase expression were observed using a 
DNA:Lipofectamine ® ratio of 1: 5 (μg/μl) on day 3 after trans-
fection, using culture medium at pH 7, and in the presence 
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line  [4, 5] . Several therapies may need to be trialled to 
achieve remission of the disease, all of which have poten-
tially severe toxicities. The development of novel thera-
peutics is therefore an interesting and important area for 
study, and gene therapy is a promising therapeutic strat-
egy. Although gene therapy has not turned out to be the 
game-changing new treatment for many intractable con-
ditions, it may still prove to be useful in combination with 
other modalities of treatment. 
 The accessibility of the skin makes diseases such as PG 
an attractive target for gene therapy. Liposomes are an 
ideal vector in this setting. Liposomes are spherical vesi-
cles characterised by lipid bilayers and are formed upon 
hydration of a dry lipid film. Liposomes resemble small 
cellular organelles  [6] and have high potential as low-tox-
icity drug carriers. Successful transfection in vitro with 
liposomes was first described in 1987  [7] , and their use in 
gene transfer has been investigated  in vitro in a wide 
range of cell lines  [8–13] , as well as in vivo  [14] . Being 
non-viral vectors, liposomes have a superior safety profile 
and acceptability compared to their viral counterparts 
 [15, 16] , as well as the ability to carry larger nucleic acid 
sequences  [16, 17] .
 Whilst many groups have investigated lipofection as a 
method of gene transfer in vitro, there is no optimised 
transfection protocol for its use in epidermal cell lines. 
Furthermore, in relation to skin disease, and specifically 
PG, no studies have investigated the effect of the drugs 
used currently in clinical management on the efficiency 
of gene transfer. This is particularly noteworthy, given 
that any future gene therapy strategy would likely be used 
alongside at least one of these drugs.
 This study therefore aimed to determine the optimum 
conditions for in vitro  transfection of the HaCaT (kera-
tinocyte) cell line using the liposomal vector Lipo-
fectamine ® 2000 with a lacZ reporter gene, and, subse-
quently, to determine the effect on transfection of the 
presence, during cell culture and transfection, of drugs 
commonly used in the treatment of PG, i.e. hydrocorti-
sone, infliximab and methotrexate.
 Materials and Methods 
 Cell Lines and Culture Conditions 
 All media and supplements were obtained from: PAA Labora-
tories Ltd., Yeovil, UK; Invitrogen Life Technologies, Paisley, UK; 
Sigma-Aldrich Co. Ltd., Gillingham, UK. HaCaT cells (derived 
from transformed human epithelium)  [18] were grown in Dul-
becco’s minimum essential medium supplemented with 10% foe-
tal bovine serum and 1% penicillin-streptomycin solution. Cells 
were grown in a humidified incubator at 37   °   C, with a 5% carbon 
dioxide atmosphere. For experiments investigating the presence of 
drugs, hydrocortisone, methotrexate or infliximab was added to 
the culture medium, diluted to the relevant concentration, as pre-
viously described  [19–21] .
 Plasmid DNA Preparation 
 The β-galactosidase (β-gal) expression plasmid pCMVβ, con-
taining the  Escherichia coli  LacZ gene under the control of the cy-
tomegalovirus immediate-early promoter, was used in transfec-
tion of HaCaT cells. A QIAGEN plasmid mini kit was used in plas-
mid preparation, as per the manufacturer’s instructions (QIAGEN 
Ltd., Crawley, UK). The concentration and purity of DNA were 
measured using UV-vis spectroscopy at 260 and 280 nm. Plasmid 
was stored at –70  °  C before use in transfection studies. 
 Experimental Conditions 
 Previous studies have shown that variation in DNA:liposome 
ratio, exposure time, and pH of the medium can affect transfection 
efficiency  [22] . However, there is no general universal optimum set 
of conditions for all cell types and transfectants, and therefore con-
ditions must be optimised for each specific combination.
 DNA:Lipofectamine ® Ratio. Cells were transfected using plas-
mid DNA and Lipofectamine ® at varying relative concentrations. 
The Lipofectamine ® variant used was Lipofectamine ® 2000. The 
DNA concentration in each well was maintained at 1 μg in 25 μl 
OptiMEM reduced-serum medium. The volume of Lipo-
fectamine ® was varied from 1 to 10 μl and made up to a total of 25 
μl with OptiMEM. This produced DNA/Lipofectamine ® ratios 
(μg/μl) of 1: 1, 1: 2, 1: 5, and 1: 10. Whilst it would be preferable to 
express these ratios as weight, molar or charge equivalents, the 
manufacturer of Lipofectamine ® does not provide the concen-
tration of their transfection reagent as it is deemed proprietary in-
formation. The manufacturer’s protocol however recommends 
DNA: Lipofectamine ® ratios of 1: 2 to 1: 5, and so our ranges of 
ratios were selected to include these recommended ratios and ex-
plore the use of Lipofectamine ® at lower (1: 1 μg/μl) and higher (10: 
 1 μg/μl) relative amounts.
 Incubation Time of Transfected HaCaT Cells. HaCaT cells were 
transfected using plasmid DNA and Lipofectamine ® in a ratio of 
1: 5. β-gal expression was measured on day 0 (4 h after transfec-
tion), and days 1, 3, 5, 7, 9, and 11 after transfection.
 pH of Culture Medium. The physicochemical properties of the 
solution in which DNA-liposome complexes form and in which 
they interact with cells affect transfection. Furthermore, skin pH 
may vary, particularly in the context of use of additional creams 
and emollients. 1  M NaOH or 5  M HCl was added to the OptiMEM 
reduced-serum medium used in transfection to achieve solu-
tions of pH 5, 6, 7, 8, and 9. pH was measured using a pH probe. 
HaCaT cells were transfected using the relevant medium and 
a DNA:Lipofectamine ® ratio (μg/μl) of 1: 5, and gene expression 
was measured 24 h after transfection.
 Presence of Drugs. HaCaT cells were grown before and after 
transfection in culture medium containing hydrocortisone, in-
fliximab, or methotrexate, at the relevant concentrations. The 
DNA:Lipofectamine ® ratio used was 1: 5. Mean transgene expres-
sion was calculated for each drug treatment on days 0 (4 h), 1, 3, 5, 
7, 9, and 11 after transfection.
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 Gene Delivery 
 Cells were seeded into 24-well tissue culture grade plates at a 
density of 5 × 10 4 cells/well with 0.5 ml culture medium. Plates 
were incubated at 37   °   C in 5% CO 2 for 24 h until approximately 
80% confluent. Before transfection, cells were washed with phos-
phate-buffered saline (PBS), and the medium on the cells was re-
placed with OptiMEM reduced-serum medium. 1 μg DNA was di-
luted into 25 μl OptiMEM, and the appropriate amount of Lipo-
fectamine ® was diluted separately in a total of 25 μl with OptiMEM 
in order to achieve the required DNA:Lipofectamine ® ratio, for 
example, 5 μl Lipofectamine ® to achieve a 1: 5 ratio. The diluted 
DNA and Lipofectamine ® suspensions were combined and incu-
bated at room temperature for 20 min to allow complexes to form. 
150 μl OptiMEM was then added to the complexes, and the di-
luted complexes were laid over the cells. For experiments investi-
gating the effect of pH, 1  M NaOH or 5  M HCl was added to the 
OptiMEM solution to achieve the required pH. Cells were incu-
bated with the complexes at 37   °   C in 5% CO 2 for 5 h, after which 
time the medium was replaced with fresh, complete growth me-
dium, except in those experiments in which β-gal expression was 
measured 4 h after transfection. In all other experiments, cells were 
re-incubated until assay for β-gal expression.
 β-Galactosidase Assay 
 β-gal expression was measured 24 h after transfection, except 
in those experiments in which timing from transfection to assay 
was the variable under investigation, where the β-gal assay was 
performed at the relevant time after transfection, as stated. Cells 
were stained using a β-gal staining kit (Invitrogen Life Technolo-
gies). Before staining, cells were rinsed with PBS and fixed with 
fixative solution for 10 min at room temperature. Cells were then 
rinsed twice with PBS, before the addition of 150 μl staining solu-
tion to each well, ensuring even coverage of the cells. Cells were 
incubated covered by the staining solution for 2 h at 37   °   C in 5% 
CO 2 .
 Quantification of Transgene Expression 
 Cells were viewed at a magnification of ×200. Random fields of 
view were photographed using an Olympus Moticam TM 2300 at-
tached to the microscope. 10 fields of view per well were photo-
graphed in tests of DNA:Lipofectamine ® ratio (3 wells for each 
ratio tested; n = 30) and 1 per well in all other tests (24 wells for 
each value tested; n = 24). From each photograph, the number of 
stained cells (expressing β-gal) were counted and expressed as a 
percentage of the total cells; these values were used to calculate the 
average percentage transfection for each data set.
 Statistical Analysis 
 Data are expressed as the percentage of cells stained positive for 
gene expression. Statistical analysis was performed using one- and 
two-way ANOVAs to compare expression between data sets and 
experiments. Tukey’s multiple comparison test and Bonferroni’s 
post tests were done to determine significance, and the null hy-
pothesis was rejected at p < 0.05.
 Results 
 Optimisation of DNA:Lipofectamine ® Ratio 
 Knowledge of the optimal ratio of plasmid DNA to li-
posome is necessary prior to the development of any 
gene therapy-based product for the skin. Variation in the 
DNA:Lipofectamine ® ratio had a significant effect on 
transfection efficiency, and was dose dependent ( fig. 1 ). 
The ratio of DNA:Lipofectamine ® producing the greatest 
percentage transfection was 1: 5. This led to a mean trans-
fection of 2.56% of cells (p < 0.001 vs. control). Ratios of 
1: 2 and 1: 10 produced much lower percentage expression 
(0.86 and 0.85%, respectively) but were still significant 
with respect to control (p < 0.01). The percentage of cells 
expressing the gene product following incubation with 
the 1: 5 ratio was significantly higher compared to both 
1: 2 and 1: 10 (p < 0.001). The level of expression from a 1: 1 
(μg/μl) ratio was not significant. No β-gal expression was 
seen with any of the negative controls, indicating that 
treatment with DNA or Lipofectamine ® alone, or with 
neither, is not sufficient for transfection.
 Optimisation of Incubation Time for HaCaT 
Transfection 
 Determination of the time over which a cell must be 
exposed to a DNA-liposome complex may be particular-
ly important in vivo, as this may be limited by natural 
processes, such as desquamation of the epidermis. This 
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 Fig. 1. Optimisation of the DNA:Lipofectamine 2000 ratio. Ratios 
are expressed as micrograms per microlitre. Each value represents 
the mean ± SEM.  * *  p < 0.01,  * * *  p < 0.001: statistically significant 
value compared to control. Lipof. = Lipofectamine ® 2000. 
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will also likely have a bearing on dosing and reapplication 
schedules. The greatest expression was seen on day 3 after 
transfection ( fig. 2 ,  3 a), with 7.60% of cells transfected. 
This result was significant with respect to day 0 (p < 
0.001), but not significant compared to days 1 or 5, on 
which 6.51 and 5.81% transfection was achieved, respec-
tively. Days 9 and 11 after transfection did not show sig-
nificant results ( fig. 2 ).
 Optimisation of pH for Transfection of HaCaT Cells 
 The physicochemical properties of the solution in 
which the anionic DNA and cationic liposomes interact 
with each other and with cells are some of the most im-
portant factors affecting transfection. We found that a 
transfection environment at pH 7 ( fig.  3 b) led to the 
greatest β-gal expression ( fig.  4 ), with 12.43% of cells 
transfected. This was significant with respect to both pH 
6 (p < 0.001) and pH 8 (p < 0.001), at which 5.43 and 
7.10% transfection was achieved, respectively. 
 Effect of Drugs on Transfection Efficiency 
 The effect of three of the drugs commonly used to treat 
PG on the efficiency of reporter gene expression into ke-
ratinocytes was studied. Cells were grown and transfected 
in medium containing hydrocortisone, infliximab, meth-
otrexate or no drug, and gene expression was measured 
on days 0–11, as previously described. Treatment of cells 
with hydrocortisone gave the greatest transfection effi-
ciency on all days except day 7 ( fig.  5 ). The enhanced 
transfection with hydrocortisone was significant com-
pared to no drug treatment on days 1, 5 and 11 after trans-
fection (p < 0.05, p < 0.05, p < 0.01, respectively). Simi-
larly, percentage transfection in hydrocortisone-treated 
cells was significant compared to infliximab-treated cells 
on the same days (p < 0.001, p < 0.05, p < 0.01, respec-
tively). Hydrocortisone caused significantly greater ex-
pression compared to methotrexate on all days where 
gene expression was apparent. Treatment with metho-
trexate produced significantly lower gene expression on 
days 1, 3, 5, and 7 than in all other groups, and signifi-
cantly less expression on days 9 and 11 than treatment 
with hydrocortisone (p < 0.05, p < 0.001, respectively). 
Transfection achieved with infliximab was generally low-
er but not significantly different from that achieved with 
no drug treatment on any day. The highest percentage 
transfection was achieved on day 3 in all treatment groups 
(including no drug treatment) except hydrocortisone-
treated cells ( fig. 3 c), in which the greatest β-gal expres-
sion (8.91%) was seen on day 1 after transfection ( fig. 5 ). 
This was not significant compared to day 3 or 5 after 
transfection (p > 0.05), but was significant with respect to 
day 0 (p < 0.001) and day 7 onwards (p < 0.05). The high-
est transfection rate in cells treated with infliximab 
( fig. 3 d) was seen on day 3 after transfection ( fig. 5 ). This 
was significant with respect to day 0 (p < 0.001), but not 
compared to days 1 or 5 after transfection (p > 0.05). In-
terestingly, the level of expression increased from day 9 
to day 11 after transfection in both the hydrocortisone- 
and infliximab-treated cells, but this difference was not 
statistically significant (p > 0.05) and may have been due 
to the chance distribution of transfected cells in the ran-
dom fields of view selected. Treatment of cells with meth-
otrexate ( fig. 3 e) produced the highest transfection rate 
on day 3 after transfection ( fig. 5 ), which was significant 
compared to days 0–1 (p < 0.001) and days 7–11 (p < 
0.001), but not compared to day 5 (p > 0.05). No β-gal 
expression was seen in methotrexate-treated cells on day 
11, in contrast to cells treated with other drugs.
 Discussion 
 PG is an uncommon yet debilitating skin disorder, for 
which there is currently no specific or targeted therapy. 
Existing treatments are used with varying success and ex-
pose patients to potentially severe side effects. There is 
therefore a need for the development of novel therapies, 
of which gene therapy may be promising. The skin is an 
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 Fig. 2. Keratinocyte expression of β-gal on days 0–11. Data are ex-
pressed as percentage of cells with β-gal activity with respect to the 
total number of cells. Each value represents the mean ± SEM.  * *  p < 
0.01,  * * *  p < 0.001: statistically significant value compared to day 0. 
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a
b
c
d
e
 Fig. 3. Representative photographs showing β-gal expression anal-
ysis of keratinocytes measured on day 3 after transfection (no drug 
treatment,  a ), cultured and transfected at pH 7 ( b ), cultured and 
transfected in medium containing hydrocortisone on day 3 after 
transfection ( c ), infliximab on day 3 after transfection ( d ), and 
methotrexate on day 3 after transfection ( e ). Blue colour (in the 
online version only) indicates cells expressing β-gal after staining. 
Original magnification ×200. 
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accessible target for gene therapy, both for direct in vivo 
 application of therapeutic agents, as well as ex vivo trans-
fection and transplantation of target cells to affected areas 
 [23, 24] . However, given its dynamic nature, involvement 
of multiple native and migratory cell types, and constant 
renewal, successful transfection of the involved cells is a 
challenge. Here, we have defined some of the environ-
mental parameters for the optimal transfection of kerati-
nocytes, the cells thought to play a pivotal role in the dis-
ease pathophysiology. Furthermore, we have determined 
the effect of the concurrent use of three of the drugs cur-
rently used in the treatment of PG, which will impact on 
the clinical application of future gene therapy strategies 
for this disease.
 The relative concentrations of DNA and Lipofec-
tamine ® are critical to transfection efficiency. The con-
centration of Lipofectamine ® becomes limiting when it is 
low relative to that of DNA, and DNA is not taken up into 
cells. Skin cells are one of the few targets in which naked 
DNA may be taken up  [25] , but in most reported cases 
the DNA was present at high concentrations and chemi-
cal enhancers were present  [26] . In this instance this 
seems unlikely, as supported by the lack of transfection in 
the control system lacking Lipofectamine ® . Where the 
concentration of Lipofectamine ® is high relative to that 
of DNA, the transfection efficiency may be similarly re-
duced because the amount of DNA is limiting, or due to 
Lipofectamine ® toxicity. Several liposomes, including Li-
pofectamine ® , have been shown to be cytotoxic  [27, 28] , 
increasingly so at higher concentrations  [27] , due to lipo-
some-induced apoptosis through caspase activation and 
reactive oxygen species generation  [28, 29] . In addition, 
DNA-liposome complexes can tend to form large aggre-
gates, particularly at higher lipid concentrations  [22] . 
Our finding of an optimum DNA:Lipofectamine ® ratio 
of 1: 5 is supported in the literature in various cell lines 
 [22, 30–32] .
 The time from introduction of transfection reagents to 
measurement of transfection had a significant impact on 
gene expression. The time required for the uptake of 
DNA-liposome complexes has been demonstrated to be 
6 h  [33] , which supports our finding of a lack of transgene 
expression at 4 h (day 0), and the increase by 24 h (day 1) 
after transfection. Caplen et al.  [22] found that under 
standard transfection conditions, transfection efficiency 
increased as the duration of incubation of cells with com-
plexes increased. Previous studies have reported peak 
gene expression to occur within the first 48 h after trans-
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 Fig. 4. Keratinocyte expression of β-gal at pH 5–9. Data are ex-
pressed as percentage of cells with β-gal activity with respect to the 
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 * * *  p < 0.001: statistically significant value. 
 Fig. 5. Keratinocyte expression of β-gal after culture and transfec-
tion in the presence of hydrocortisone, infliximab, methotrexate, 
and no drug. Data are expressed as percentage of cells with β-gal 
activity with respect to the total number of cells. Each value repre-
sents the mean ± SEM.  *  p < 0.05,  * *  p < 0.01,  * * *  p < 0.001: statis-
tically significant value compared to no drug treatment. 
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fection  [34] , and 48–96 h (day 2–4) after transfection  [35, 
36] . Furthermore, a precise time period of 3 days was re-
ported by de la Monte and Wands  [37] as showing maxi-
mal gene expression. In our study, cells were transfected 
and incubated with the transfection reagents for 5 h, un-
der standard conditions. Following this, the reagents 
were replaced with fresh, complete growth medium. A 
longer duration from transfection to measurement of 
gene expression allows more time for transcription and 
translation of the DNA once it has been taken into the 
cell, leading to greater gene expression, as shown by the 
increase in expression from day 0 to day 3. Following this 
time of peak expression, as the DNA is cleared, the mea-
sured gene expression will reduce. Due to limiting bio-
logical processes, in vivo any given cell may only be ex-
posed to complexes transiently, and so reapplication of 
gene therapy products at optimal intervals would be nec-
essary.
 Amongst factors influencing transfection, the physi-
cochemical properties of the solution, in which DNA-li-
posome complexes form and interact with cells, are high-
ly important. Cationic Lipofectamine ® 2000 and anionic 
DNA must interact electrostatically in order to form 
complexes, and the state of protonation in the transfec-
tion system is an important rate-limiting step  [38] . Fur-
thermore, in gaining entry to the cell, positively charged 
complexes interact with the relative negative charge of the 
plasma membrane; entry of negatively charged complex-
es is prevented  [39] . Local pH alters the state of proton-
ation in the transfection system and has an important 
bearing on transfection efficiency. The sensitivity of lipo-
somes to pH may additionally be taken advantage of in 
certain situations, by designing pH-sensitive liposomes 
and other nanoparticles that are stable at physiological 
pH but become unstable at lower pH such as those found 
in diseased tissue, releasing the DNA or drug they are car-
rying  [40, 41] . This study has found the optimum pH for 
transfection of the HaCaT cell line, under the conditions 
used, to be pH 7. The optimum pH for transfection has 
been reported by other authors to be pH 9  [22] , pH 8  [38] , 
and pH 7  [39] . Optimum pH may, however, vary accord-
ing to the liposome vector and to the solution, as well as 
cell line factors.
 If a topical gene therapy is to be developed for condi-
tions such as PG, additional external factors such as the 
effect of drugs that the patient may also be using for the 
condition must be taken into account, as these may influ-
ence the efficiency of gene transfer. This study is the first 
to investigate the effect on gene transfection of three 
drugs which are commonly used to treat PG, and has 
shown that a significantly positive effect was exerted by 
hydrocortisone. Hydrocortisone is a glucocorticoid, one 
of the most powerful immunosuppressive and anti-in-
flammatory groups of drugs  [42] , and is a first-line ther-
apy for PG  [2, 5, 43] . The effect of hydrocortisone on ke-
ratinocyte survival and proliferation is disputed. Some 
authors report promotion of proliferation  [44, 45] , while 
others report induction of apoptosis  [42] . However, be-
cause transfection was reported as a proportion of total 
cells, this effect would have been minimal. Regardless of 
an effect on cellular proliferation, hydrocortisone has 
been shown to increase transfection efficiency in a dose-
dependent manner  [46, 47] . Lin et al.  [48] reported a 
dose-dependent increase in transgene expression in mul-
tiple cell lines in vitro  and in vivo when hydrocortisone 
was used with adenovirus vectors. This enhancement was 
shown when hydrocortisone was added before, together 
with, and after the vector. Corticosteroids play a major 
physiological role in the regulation of gene transcription 
and protein synthesis in all cells, and this may influence 
transgene expression in this way. Additionally, they may 
alter cell membrane fluidity and permeability due to their 
lipophilic nature, allowing entry of DNA:vector complex-
es  [48] .
 Conversely, we showed that methotrexate significant-
ly impaired transfection of keratinocytes. Methotrexate is 
cytotoxic, acting via the inhibition of purine and pyrimi-
dine synthesis, hence its use in the treatment of inflam-
matory diseases  [49] . In keratinocytes, methotrexate has 
been found to inhibit proliferation and alter cell mor-
phology in vitro  [50] , and moreover to induce apoptosis 
 [51, 52] . The cytotoxic effects of methotrexate could ac-
count for the lower β-gal expression in methotrexate-
treated cells. All plates in this study were seeded to the 
same densities using cells from the same culture flask, and 
were incubated to grow for 24 h before transfection. Rep-
resentative photographs of the methotrexate-treated 
plates do, despite this, show lower cell densities than 
plates that received other drug treatments. The presence 
of fewer cells could have reduced the likelihood of trans-
fection. Dalby et al.  [8] found that reporter gene activity 
declined as cell density decreased. In the present study, 
cells treated with methotrexate which had been transfect-
ed may subsequently have been killed, leading to a de-
creased percentage expression. Additionally, cells at low 
density are more susceptible to toxic effects of transfec-
tion  [8] . There is scant work on the effects of methotrex-
ate on transfection efficiency; however, Pallavicini et al. 
 [53] found that treatment of cells with methotrexate led 
to an increased variability of the cellular location and 
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amount of transfected genes and of transgene expression. 
These factors may have contributed to the significantly 
lower transgene expression in methotrexate-treated cells.
 Within our study, despite maintaining controlled con-
ditions, there is some variability in the percentage gene ex-
pression between different experiments, with experiments 
determining optimum ratios of DNA:Lipofectamine ® 
2000 showing lower transfection than those investigating 
timings, pH, and the influence of drugs. All experiments 
were subject to the same conditions, with gene expression 
measured at the same time point (except in those experi-
ments investigating optimal timing). The variability be-
tween experiments is likely to be due to biological variabil-
ity within the cultured cells, while importantly there is very 
limited variability within each experiment, as demonstrat-
ed by the narrow error bars within each. Additionally, the 
absolute percentages of gene expression are low, even at the 
greatest level achieved. This is a reflection of the semiquan-
titative method used, in which a coloured product arising 
from an enzymatic reaction was assessed visually. The 
greatest gene expression was seen on day 3 after transfec-
tion in all experiments, except those done in the presence 
of hydrocortisone, which produced the greatest transfec-
tion on day 1, producing further variability. However, the 
expression seen on day 1 in the hydrocortisone-treated 
cells was only marginally greater than that seen on day 3, 
and this difference was not significant. The earlier peak 
expression in these cells may have been due to biological 
variability within the cells, or may be a result of enhanced 
gene transcription and protein synthesis by the hydrocor-
tisone itself. 
 This study has investigated some of the factors affect-
ing transfection of keratinocytes in vitro and may be im-
portant in the development of gene therapy for PG and 
other skin diseases. However, there are numerous other 
variables in vivo that affect the application of these results 
and should also be considered. Due to the continuous re-
generation of the epidermis, transfected cells are rapidly 
shed, and thus transgene expression is only short-lived 
 [26] . This would make regular re-application essential 
and could limit the acceptability of any gene therapy-
based treatment. However, as most patients with PG and 
other skin conditions already use multiple topical and 
systemic treatments to control the painful lesions, the im-
pact of this is likely to be reduced. In addition, wound 
healing is a complex process involving many interacting 
cell types and growth factors, which is time limited, and 
therefore transgene expression which is only temporary 
is not unfavourable  [54] . PG is a non-malignant disease, 
so a transfection rate of 100% is not required; the rela-
tively low transfection efficiency of liposomes  [15] is not 
necessarily problematic. Liposomes, as non-viral vectors, 
have the well-documented disadvantage of limited local 
effects and poor systemic penetration  [17] , but in the con-
text of skin disease, this is beneficial, the therapeutic genes 
being delivered directly to the target tissue. The skin is a 
3-dimensional structure containing multiple interacting 
cell types, and it must be borne in mind that optimum 
transfection conditions may vary between cell lines, and 
a protocol suitable for one may not be favourable for an-
other. Similar optimisation experiments have been car-
ried out by this research group in fibroblasts [unpubl. 
work], but this must be investigated for other resident 
skin cells, to produce a single effective treatment. Fur-
thermore, cells cultured as a monolayer may differ physi-
ologically from cells in vivo and are not subject to the 
same biochemical influences and cell signalling processes 
that are present in the skin as an organ. Importantly, how-
ever, successful gene delivery to excised human skin ex-
plants has been demonstrated using plasmid DNA-coat-
ed microneedles, without the need for a viral or liposomal 
vector  [55] , and several other physical methods of gene 
delivery exist  [56] . This, together with the development 
of ex vivo skin models  [57, 58] , is promising for the future 
of gene therapy for skin conditions, and these models 
should be studied further as an intermediate between in 
vitro and in vivo studies. Moreover, healthy keratinocytes 
in culture systems are characteristically different from 
those in ulcers of PG, and disease models must be devel-
oped to study transfection if this work is to be relevant 
and practical in the treatment of PG.
 As the pathophysiology of PG remains unclear, thera-
peutic genes are yet to be elucidated; this continues to be 
a key area for future work. There are several possible can-
didate genes. The majority of these may be involved in 
wound healing, such as keratinocyte growth factor  [59] , 
epidermal growth factor, or members of the fibroblast 
growth factor family  [60] . Genes involved in immune reg-
ulation may also be investigated, after increasing evi-
dence of an immune aetiology for PG  [3, 61–66] . Particu-
lar immune targets may include genes encoding cell sur-
face proteins involved in neutrophil trafficking, such as 
integrins CR3 and CR4  [63] , and encoding interleukin-8, 
which recruits neutrophils to sites of infection and has 
been found to be overexpressed in PG ulcers and may be 
implicated in disease pathogenesis  [62, 64] . PG is one fea-
ture of PAPA syndrome (pyogenic arthritis, PG and acne) 
 [1, 67, 68] , an autosomal-dominantly inherited disease. 
The genetic defect in this syndrome has been mapped to 
chromosome 15q  [69] and is caused by mutations in the 
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PSTPIP1 gene, which encodes CD2 binding protein 1, in-
volved in regulation of the inflammatory response  [70, 
71] . A further syndrome, PG, acne and suppurative hi-
dradenitis (PASH), has also been described in unrelated 
individuals, and may or may not have an underlying ge-
netic component  [72] . Further elucidation of these ge-
netic disorders may help identify targets for gene therapy 
for PG.
 In conclusion, we have identified certain conditions 
suitable for in vitro  transfection of keratinocytes, which 
may be a prelude to the successful in vivo use of gene 
therapy as a treatment strategy for PG. Furthermore, we 
examined the effect of several drugs which are currently 
used in the management of this disease and in practice are 
likely to be used alongside any gene therapy agent. Gene 
therapy offers some hope for the treatment of PG, a severe 
disease with currently limited treatment options. This 
strategy is already being trialled for the treatment of oth-
er cutaneous conditions  [73–76] . In vitro  optimisation 
studies such as this, together with progression of under-
standing of the pathophysiological mechanisms behind 
PG, are necessary for a similar approach to the treatment 
of PG. 
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